Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Avalo Therapeutics (AVTX) Shares Outstanding (2016 - 2023)

Historic Shares Outstanding for Avalo Therapeutics (AVTX) over the last 10 years, with Q2 2023 value amounting to $14.0 million.

  • Avalo Therapeutics' Shares Outstanding rose 4923.83% to $14.0 million in Q2 2023 from the same period last year, while for Jun 2023 it was $14.0 million, marking a year-over-year increase of 4923.83%. This contributed to the annual value of $9.4 million for FY2022, which is 33.0% up from last year.
  • Latest data reveals that Avalo Therapeutics reported Shares Outstanding of $14.0 million as of Q2 2023, which was up 4923.83% from $13.2 million recorded in Q1 2023.
  • In the past 5 years, Avalo Therapeutics' Shares Outstanding ranged from a high of $74.9 million in Q2 2020 and a low of $6.3 million during Q4 2020
  • For the 5-year period, Avalo Therapeutics' Shares Outstanding averaged around $27.2 million, with its median value being $11.3 million (2022).
  • Its Shares Outstanding has fluctuated over the past 5 years, first soared by 7459.93% in 2020, then crashed by 8931.81% in 2021.
  • Quarter analysis of 5 years shows Avalo Therapeutics' Shares Outstanding stood at $44.4 million in 2019, then crashed by 85.92% to $6.3 million in 2020, then skyrocketed by 50.38% to $9.4 million in 2021, then rose by 0.33% to $9.4 million in 2022, then surged by 48.85% to $14.0 million in 2023.
  • Its last three reported values are $14.0 million in Q2 2023, $13.2 million for Q1 2023, and $9.4 million during Q4 2022.